|
|
|
|
|
19.01.26 - 07:36
|
Wihlborgs signs agreement with Baravaragruppen for restaurant at Helsingborg C (Cision)
|
|
|
Wihlborgs' continued development of Helsingborg C (Terminalen 1) takes the next step as the Helsingborg-based restaurant and entertainment group Baravaragruppen AB establishes operations at the transport hub. In spring 2026, a new concept covering 600 square metres will open.
Baravaragruppen has been operating in Helsingborg since 1999 and currently runs a number of restaurants and venues with different profiles, including Bara Vara, Sillen & Makrillen, D35, Jacob Hansens Hus, The Tivoli and Helsingborg Live. In 2026, the group will also establish itself one floor up at Helsingborg C, where...
|
|
|
|
|
|
|
07.01.26 - 08:00
|
Third Point Master Fund December 2025 Performance (Cision)
|
|
|
7 January 2026
Third Point Master Fund1
Monthly Update: December 2025 Performance
December 2025 Performance Highlights
· Third Point Offshore Fund, Ltd. returned 0.7% in December 2025.
· The top contributors for the month included transportation company DSV A/S, enterprise technology company Nvidia Corp., and financial company Capital One Financial Corp.
· The top detractors for the month included infrastructure software company Microsoft Corp., a private company, and media and internet company Informa PLC.
Net Performance
+--------------------------------...
|
|
|
|
|
|
|
23.12.25 - 20:01
|
FDA Clears Wegovy Pill | Open Interest 12/23/2025 (Bloomberg)
|
|
|
Get a jump start on the US trading day with Matt Miller and Vonnie Quinn on "Bloomberg Open Interest." A weight-loss game changer. Novo Nordisk wins FDA approval for a Wegovy pill, launching next month. And a billionaire bet with billions on the line — Larry Ellison's $40 billion pledge to back Paramount's bid for Warner Bros. No slowdown in growth: US GDP jumps to a two-year high, even as consumer confidence slips again. Plus, The Points Guy's Brian Kelly joins Bloomberg Open Interest on navigating new travel rules this holiday season. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
04.12.25 - 15:03
|
TextNow Names Industry Expert Casey Forbes SVP of Sales (Business Wire)
|
|
|
SAN FRANCISCO & WATERLOO, Ontario--(BUSINESS WIRE)--TextNow, the leading ad-supported free phone service in the U.S., today announced the appointment of Casey Forbes as Senior Vice President of Sales. Casey will lead the company's growing sales organization and accelerate partnerships that help drive ad revenue, allowing the company to expand their free wireless services for millions of users.
A longtime leader in audio and digital advertising, Casey brings more than two decades of experience from senior roles at SiriusXM, Pandora, and Crystal Media Networks. She has a proven track record of building high-performing teams, launching new ad products, and driving major revenue growth across diverse audiences.
At TextNow, Casey will work closely with product teams to create new, high-impact advertising opportunities designed to connect brands with highly engaged mobile audiences on TextNow's app, which has been downloaded more than 300 million times globally. These partnerships play a critical role in Text...
|
|
|
28.11.25 - 16:09
|
Disclosure of major shareholder announcement (GlobeNewswire EN)
|
|
|
In accordance with section 30, cf. section 38, of the Danish Capital Markets Act, Tivoli A/S hereby announces that Augustinus Fonden has today notified Tivoli A/S that Augustinus Fondens wholly owned subsidiary Skandinavisk Holding A/S has disposed its directly owned shares in Tivoli A/S in connection with, and as a result of, the completion of the merger between Skandinavisk Holding A/S (the discontinuing company) and the Augustinus Foundation's wholly owned subsidiary Chr. Augustinus Fabrikker Aktieselskab (the continuing company)....
|
|
|
|
|
|
|
|
|
|
|
24.11.25 - 14:39
|
Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer′s Trials - Shares Suffer Worst Year Ever (ZeroHedge)
|
|
|
Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer's Trials - Shares Suffer Worst Year Ever
Shares of Novo Nordisk in Copenhagen plunged the most in nearly four months after top-line results from a two-year analysis of the evoke and evoke+ Phase 3 trials, a pill version of Ozempic, showed the treatment failed to slow progression in early-stage symptomatic Alzheimer's disease.
The studies, which enrolled 3,808 adults over two years, found improvements in Alzheimer's-related biomarkers but no meaningful impact on cognitive decline, as measured by the Clinical Dementia Rating (CDR-SB) score.
"While treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers in both trials, this did not translate into a delay of disease progression," Novo wrote in a press release.
Novo chief scientific officer Martin Holst Lange commented on the results:
"Based on the significant unmet need in Alzheimer's disease as well as a number of indicative dat...
|
|
|
24.11.25 - 13:24
|
Wdh: Abnehmmittel als Alzheimer-Hoffnung: Novo Nordisk enttäuscht mit Studie (Cash)
|
|
|
- Das Abnehmmittel Semaglutid des Pharmakonzerns Novo Nordisk hat in einer Alzheimer-Studie nicht den erwünschten Erfolg gebracht. Die zulassungsrelevante Phase-III-Studie Evoke zu Semaglutid in oraler Darreichungsform habe im Vergleich zu Placebo keine statistisch signifikante Verlangsamung des Fortschreitens der Alzheimer-Krankheit gezeigt, teilte der dänische Pharmariese am Montag mit. Der Aktienkurs von Novo Nordisk brach auf die Nachricht hin um zehn Prozent auf den tiefsten Stand seit dem Jahr 2021 ein./mis/stw...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
